Black Diamond Therapeutic... (BDTX)
NASDAQ: BDTX
· Real-Time Price · USD
2.21
-0.04 (-1.78%)
At close: May 30, 2025, 3:59 PM
2.18
-1.58%
After-hours: May 30, 2025, 05:57 PM EDT
-1.78% (1D)
| Bid | 2.12 |
| Market Cap | 125.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 5.09M |
| EPS (ttm) | 0.06 |
| PE Ratio (ttm) | 36.92 |
| Forward PE | -2.2 |
| Analyst | Buy |
| Ask | 2.26 |
| Volume | 871,398 |
| Avg. Volume (20D) | 3,429,033 |
| Open | 2.23 |
| Previous Close | 2.25 |
| Day's Range | 2.12 - 2.26 |
| 52-Week Range | 1.20 - 6.75 |
| Beta | 2.64 |
About BDTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BDTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BDTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+2.38%
Black Diamond Therapeutics shares are trading high...
Unlock content with
Pro Subscription
8 months ago
-5.46%
Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.
2 months ago · seekingalpha.com
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With ServierBlack Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash ...
